Abstract
Graft-versus-host disease (GVHD) remains a major complication of allogeneic haemopoietic stem cell transplantation (HSCT) and is one of the main causes of non-relapse mortality and poor quality of life. Treatment of GVHD is associated with long-lasting exposure to immunosuppressive treatment and related morbidity, therefore GVHD prevention is crucial to improve outcomes after transplantation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
